Related Experiment Video

Updated: May 28, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Bevacizumab treatment for advanced breast cancer

Ricardo H Alvarez1, Valentina Guarneri, Fikri Icli

  • 1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-3721, USA. ralvarez@mdanderson.org

The Oncologist
|October 7, 2011
PubMed

Insights

Bevacizumab, an antibody targeting vascular endothelial growth factors (VEGFs), enhances taxane efficacy in metastatic breast cancer treatment. This review examines studies combining bevacizumab with chemotherapy for advanced breast cancer.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Breast cancer treatment has advanced with targeted therapies beyond traditional chemotherapy.
  • Small molecules and monoclonal antibodies targeting tyrosine kinase receptors improve outcomes.
  • Novel cancer targets and therapeutic approaches are emerging.

Purpose of the Study:

  • To review promising breast cancer studies using bevacizumab with cytotoxic agents in advanced disease.
  • To discuss current indications for bevacizumab reviewed by the Oncologic Drug Advisory Committee.
  • To define metrics for measuring patient clinical trial benefits.

Main Methods:

  • Review of clinical studies on bevacizumab combined with traditional cytotoxic agents.
  • Analysis of data on bevacizumab's efficacy in advanced breast cancer.
  • Discussion of regulatory reviews and clinical trial outcome measures.

Main Results:

  • Bevacizumab, a monoclonal antibody against VEGF, improves taxane efficacy in metastatic breast cancer.
  • Combination therapy with bevacizumab and cytotoxic agents shows promise in advanced breast cancer.
  • Evidence supports bevacizumab's role in specific breast cancer treatment regimens.

Conclusions:

  • Bevacizumab represents a significant advancement in targeted therapy for advanced breast cancer.
  • Further research and clear outcome measures are crucial for optimizing bevacizumab use.
  • The combination of bevacizumab with chemotherapy offers improved efficacy in select breast cancer patients.

More Related Videos

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...